For the Inventor, By the Inventor

Enter assignee name

Redwood City, CA, United States of America

Revolution Medicines, Inc.

USPTO Granted Patents = 40

EPO Patents = 10

Trademarks = 10

Forward Citations = 173

Loading Chart...

Loading Chart...

79 inventors (with patents filed for the assignee):

Adrian L Gill (24 out of 24 patents)

Elena S Koltun (21 out of 34 patents)

James Joseph Cregg (18 out of 23 patents)

4. Andreas Buckl (14 out of 14 patents)

5. G Leslie Burnett (11 out of 12 patents)

6. Yang Liu (11 out of 19 patents)

7. Christopher Michael Semko (11 out of 11 patents)

8. Naing N Aay (11 out of 20 patents)

9. Jennifer Pitzen (10 out of 11 patents)

10. Walter Won (10 out of 23 patents)

11. Gert Kiss (9 out of 9 patents)

12. Kevin T Mellem (8 out of 12 patents)

13. Gregory Lawrence Verdine (7 out of 85 patents)

14. James Bradley Aggen (6 out of 7 patents)

15. Gang Wang (6 out of 6 patents)

Core Competencies:

SHP2 Inhibitors

mTOR Inhibitors

Ras Inhibitors

Bicyclic Heteroaryl Compounds

Cooperative Binding

Pyrazine Compounds

Therapeutic Agents

Protein-Protein Interfaces

Solid Forms

Analog Compounds

40 patents: Sort by Forward Citations

1. 12662707 - MYC amplification drives resistance to pan-RAS inhibitors in pancreatic cancer (2026-06-23),

2. 12624053 - Ras inhibitors (2026-05-12),

3. 12587381 - Method and system for monitoring and controlling high risk substances (2026-03-24),

4. 12565476 - 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors (2026-03-03),

5. 12528807 - Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitor (2026-01-20),

6. 12409225 - Ras inhibitors (2025-09-09),

7. 12403196 - Ras inhibitors (2025-09-02),

8. 12384750 - Ras inhibitors (2025-08-12),

9. 12365688 - Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors (2025-07-22),

10. 12280113 - Ras inhibitors (2025-04-21),

11. 12258366 - Bicyclic heteroaryl compounds and uses thereof (2025-03-25),

12. 12252497 - Ras inhibitors (2025-03-18),

13. 12202845 - Ras inhibitors (2025-01-21),

14. 12187746 - C26-linked rapamycin analogs as mTOR inhibitors (2025-01-07),

15. 12121522 - Methods of treating cancer with an mTOR inhibitor (2024-10-22),

Company Overview

Revolution Medicines, Inc. is a biotechnology company based in Redwood City, California, focused on developing innovative therapies for cancer treatment. The company specializes in the discovery and development of targeted medicines that aim to address the underlying genetic drivers of cancer. By leveraging advanced drug discovery technologies, Revolution Medicines seeks to create effective treatments that improve patient outcomes and enhance the quality of life for individuals affected by cancer.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

40 Patents

#55 in Redwood City, CA

#2,038 in California

#8,628 in US

#17,068 in the World

Redwood City, CA, United States of America

Revolution Medicines, Inc.

Forward Citations = 173

79 inventors:

Adrian L Gill (24 out of 24 patents)

Elena S Koltun (21 out of 34 patents)

James Joseph Cregg (18 out of 23 patents)

4. Andreas Buckl (14 out of 14 patents)

5. G Leslie Burnett (11 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Revolution Medicines, Inc.. Retrieved from https://idiyas.com/company/revolution-medicines

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…